Cargando…
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
IMPORTANCE: There is a need to identify prognostic biomarkers to guide treatment intensification in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). OBJECTIVE: To examine whether molecular subtypes predict response to apalutamide, using archived primary tumor samples from t...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176389/ https://www.ncbi.nlm.nih.gov/pubmed/34081076 http://dx.doi.org/10.1001/jamaoncol.2021.1463 |
_version_ | 1783703251164594176 |
---|---|
author | Feng, Felix Y. Thomas, Shibu Saad, Fred Gormley, Michael Yu, Margaret K. Ricci, Deborah S. Rooney, Brendan Brookman-May, Sabine McCarthy, Sharon Olmos, David Chowdhury, Simon Hadaschik, Boris Liu, Yang Davicioni, Elai Smith, Matthew R. Small, Eric J. |
author_facet | Feng, Felix Y. Thomas, Shibu Saad, Fred Gormley, Michael Yu, Margaret K. Ricci, Deborah S. Rooney, Brendan Brookman-May, Sabine McCarthy, Sharon Olmos, David Chowdhury, Simon Hadaschik, Boris Liu, Yang Davicioni, Elai Smith, Matthew R. Small, Eric J. |
author_sort | Feng, Felix Y. |
collection | PubMed |
description | IMPORTANCE: There is a need to identify prognostic biomarkers to guide treatment intensification in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). OBJECTIVE: To examine whether molecular subtypes predict response to apalutamide, using archived primary tumor samples from the randomized, double-blind, phase 3 SPARTAN trial. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, gene expression data from 233 archived samples from patients with nmCRPC enrolled in the SPARTAN trial were generated using a human exon microarray. The present analysis was conducted from May 10, 2018, to October 15, 2020. INTERVENTIONS: Patients were randomized (2:1) to apalutamide, 240 mg/d, with androgen deprivation therapy (apalutamide+ADT) or placebo+ADT. MAIN OUTCOMES AND MEASURES: Patients were stratified into high-risk and low-risk categories for developing metastases based on genomic classifier (GC) scores for high (GC >0.6) and low to average (GC≤0.6) and into basal and luminal subtypes; associations between these molecular subtypes and metastasis-free survival (MFS), overall survival (OS), and progression-free survival 2 (PFS2) were evaluated using Cox proportional hazards regression and Kaplan-Meier analysis. RESULTS: Median age of the 233 included patients was 73 (range, 49-91) years. A total of 116 of 233 patients (50%) in the SPARTAN biomarker subset had high GC scores. Although all patients receiving apalutamide+ADT had improved outcomes, having high GC scores was associated with the greatest improvement in MFS (hazard ratio [HR], 0.21; 95% CI, 0.11-0.40; P < .001), OS (HR, 0.52; 95% CI, 0.29-0.94; P = .03), and PFS2 (HR, 0.39; 95% CI, 0.23-0.67; P = .001) vs placebo+ADT. In total, 152 of 233 patients (65%) had the basal molecular subtype. Although there were no significant differences in MFS, PFS2, or OS between patients with the luminal vs basal subtype in the placebo+ADT arm, patients with the luminal subtype in the apalutamide+ADT arm had a significantly longer MFS (apalutamide+ADT: HR, 0.40; 95% CI, 0.18-0.91; P = .03; placebo+ADT: HR, 0.66; 95% CI, 0.33-1.31; P = .23) compared with patients with basal subtype; similar trends were observed for OS (apalutamide+ADT: HR, 0.50; 95% CI, 0.25-0.98; P = .04; placebo+ADT: HR, 0.78; 95% CI, 0.38-1.60; P = .50), and PFS2 (apalutamide+ADT: HR, 0.71; 95% CI, 0.42-1.22; P = .22; placebo+ADT: HR, 0.72; 95% CI, 0.38-1.39; P = .33). In regression analysis, the luminal-basal subtype score was significantly associated with MFS in patients receiving apalutamide+ADT (HR, 2.65; 95% CI, 1.15-6.08; P = .02), whereas GC score was significantly associated with MFS in placebo+ADT recipients (HR, 2.09; 95% CI, 1.02-4.27; P = .04). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that the GC score and basal-luminal subtype derived from archived tumor specimens may be biomarkers of response to apalutamide+ADT in the nmCRPC setting. Although overall, the addition of apalutamide to ADT was beneficial, higher-risk and luminal subtypes appeared to benefit most. Obtaining GC scores may be useful for identifying patients for early treatment intensification with apalutamide, and basal-luminal subtyping may be a beneficial approach for patient selection for further treatment intensification in trials combining novel therapies with apalutamide. |
format | Online Article Text |
id | pubmed-8176389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-81763892021-06-17 Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer Feng, Felix Y. Thomas, Shibu Saad, Fred Gormley, Michael Yu, Margaret K. Ricci, Deborah S. Rooney, Brendan Brookman-May, Sabine McCarthy, Sharon Olmos, David Chowdhury, Simon Hadaschik, Boris Liu, Yang Davicioni, Elai Smith, Matthew R. Small, Eric J. JAMA Oncol Original Investigation IMPORTANCE: There is a need to identify prognostic biomarkers to guide treatment intensification in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). OBJECTIVE: To examine whether molecular subtypes predict response to apalutamide, using archived primary tumor samples from the randomized, double-blind, phase 3 SPARTAN trial. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, gene expression data from 233 archived samples from patients with nmCRPC enrolled in the SPARTAN trial were generated using a human exon microarray. The present analysis was conducted from May 10, 2018, to October 15, 2020. INTERVENTIONS: Patients were randomized (2:1) to apalutamide, 240 mg/d, with androgen deprivation therapy (apalutamide+ADT) or placebo+ADT. MAIN OUTCOMES AND MEASURES: Patients were stratified into high-risk and low-risk categories for developing metastases based on genomic classifier (GC) scores for high (GC >0.6) and low to average (GC≤0.6) and into basal and luminal subtypes; associations between these molecular subtypes and metastasis-free survival (MFS), overall survival (OS), and progression-free survival 2 (PFS2) were evaluated using Cox proportional hazards regression and Kaplan-Meier analysis. RESULTS: Median age of the 233 included patients was 73 (range, 49-91) years. A total of 116 of 233 patients (50%) in the SPARTAN biomarker subset had high GC scores. Although all patients receiving apalutamide+ADT had improved outcomes, having high GC scores was associated with the greatest improvement in MFS (hazard ratio [HR], 0.21; 95% CI, 0.11-0.40; P < .001), OS (HR, 0.52; 95% CI, 0.29-0.94; P = .03), and PFS2 (HR, 0.39; 95% CI, 0.23-0.67; P = .001) vs placebo+ADT. In total, 152 of 233 patients (65%) had the basal molecular subtype. Although there were no significant differences in MFS, PFS2, or OS between patients with the luminal vs basal subtype in the placebo+ADT arm, patients with the luminal subtype in the apalutamide+ADT arm had a significantly longer MFS (apalutamide+ADT: HR, 0.40; 95% CI, 0.18-0.91; P = .03; placebo+ADT: HR, 0.66; 95% CI, 0.33-1.31; P = .23) compared with patients with basal subtype; similar trends were observed for OS (apalutamide+ADT: HR, 0.50; 95% CI, 0.25-0.98; P = .04; placebo+ADT: HR, 0.78; 95% CI, 0.38-1.60; P = .50), and PFS2 (apalutamide+ADT: HR, 0.71; 95% CI, 0.42-1.22; P = .22; placebo+ADT: HR, 0.72; 95% CI, 0.38-1.39; P = .33). In regression analysis, the luminal-basal subtype score was significantly associated with MFS in patients receiving apalutamide+ADT (HR, 2.65; 95% CI, 1.15-6.08; P = .02), whereas GC score was significantly associated with MFS in placebo+ADT recipients (HR, 2.09; 95% CI, 1.02-4.27; P = .04). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that the GC score and basal-luminal subtype derived from archived tumor specimens may be biomarkers of response to apalutamide+ADT in the nmCRPC setting. Although overall, the addition of apalutamide to ADT was beneficial, higher-risk and luminal subtypes appeared to benefit most. Obtaining GC scores may be useful for identifying patients for early treatment intensification with apalutamide, and basal-luminal subtyping may be a beneficial approach for patient selection for further treatment intensification in trials combining novel therapies with apalutamide. American Medical Association 2021-06-03 2021-07 /pmc/articles/PMC8176389/ /pubmed/34081076 http://dx.doi.org/10.1001/jamaoncol.2021.1463 Text en Copyright 2021 Feng FY et al. JAMA Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Feng, Felix Y. Thomas, Shibu Saad, Fred Gormley, Michael Yu, Margaret K. Ricci, Deborah S. Rooney, Brendan Brookman-May, Sabine McCarthy, Sharon Olmos, David Chowdhury, Simon Hadaschik, Boris Liu, Yang Davicioni, Elai Smith, Matthew R. Small, Eric J. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title | Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title_full | Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title_fullStr | Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title_full_unstemmed | Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title_short | Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer |
title_sort | association of molecular subtypes with differential outcome to apalutamide treatment in nonmetastatic castration-resistant prostate cancer |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176389/ https://www.ncbi.nlm.nih.gov/pubmed/34081076 http://dx.doi.org/10.1001/jamaoncol.2021.1463 |
work_keys_str_mv | AT fengfelixy associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT thomasshibu associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT saadfred associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT gormleymichael associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT yumargaretk associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT riccideborahs associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT rooneybrendan associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT brookmanmaysabine associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT mccarthysharon associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT olmosdavid associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT chowdhurysimon associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT hadaschikboris associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT liuyang associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT davicionielai associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT smithmatthewr associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer AT smallericj associationofmolecularsubtypeswithdifferentialoutcometoapalutamidetreatmentinnonmetastaticcastrationresistantprostatecancer |